Novaremed’s Acquisition of Metys Pharmaceuticals

VISCHER AG advised Novaremed on the deal.

Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.

The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment.

Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments.

The Vischer team was team led by Matthias Staehelin (Picture) with Vincent Reardon, Luzius Zumstein, Cédric Saladin (all Corporate) and Nadia Tarolli with Adrian Briner (both Tax).

Involved fees earner: Adrian Briner – VISCHER AG; Vincent Reardon – VISCHER AG; Cédric Saladin – VISCHER AG; Matthias Staehelin – VISCHER AG; Nadia Tarolli – VISCHER AG; Luzius Zumstein – VISCHER AG;

Law Firms: VISCHER AG;

Clients: Novaremed AG;

Author: Federica Tiefenthaler